Donald R. Chase, who serves as a director at Bluejay Diagnostics, Inc., executed a significant acquisition of the company's common stock on March 14, 2026. This transaction involved the purchase of 12,500 shares of BJDX common stock for a total consideration of $25,000. The reported per-share price for this private placement was set at $2.00.
The timing of Mr. Chase's investment is noteworthy, as the company's stock traded near its 52-week low point of $1.65 on the date of the acquisition. On March 14, 2026, the stock was priced at $1.72, which remained substantially below the cost basis of Chase’s recent purchase.
Following this specific transaction, Mr. Chase's direct holdings in Bluejay Diagnostics common stock increased to 12,525 shares. This investment comes after a period marked by a substantial decline, as the stock had fallen by 77% over the preceding year.
Further contextual information regarding the company’s valuation is available through third-party analysis; specifically, according to InvestingPro's assessment, which provides an additional 12 ProTips for BJDX, the stock is currently assessed as undervalued based on its Fair Value determination.
The recent insider activity by Mr. Chase is set against a backdrop of significant corporate financing and structural changes within Bluejay Diagnostics. In addition to his personal purchase, the company recently finalized another private placement involving 62,500 shares of common stock. This sale was executed at $2.00 per share, generating gross proceeds totaling $125,000.
The purchasers in this larger transaction were five distinct individuals, all of whom are current members of the company's board of directors. Key participants included Neil Dey, who holds the role of President and CEO, alongside Donald Chase, who serves as the Chair of the Board.
Moreover, Bluejay Diagnostics completed a comprehensive corporate action by fully exercising all prefunded warrants originating from its private placement conducted in October 2025. This exercise concluded that no remaining prefunded warrants were outstanding. The effect of this full warrant exercise was to elevate the total number of shares of common stock outstanding to approximately 972,000.
In terms of corporate governance and ongoing relations, Bluejay Diagnostics also issued a response letter addressing correspondence it received from NorthStrive Fund II LP. While the specific content of this communication was not disclosed publicly, a copy of Bluejay’s official reply has been included as an exhibit within a recent SEC filing. These multifaceted developments collectively reflect the company's continued operational and financial activities.
The stock data provided for BJDX shows its price trading at $1.72 (with a day change of +0.05, or +2.99% as of 15:59:59). The after-hours trading price was reported at $1.83 (a gain of +0.11, representing a +6.40%).
Risks
- The article does not explicitly state operational risks, but reliance on private placements suggests ongoing need for capital funding.
- The significant decline of 77% over the past year highlights substantial volatility and market challenges faced by the stock.
- Future corporate actions (such as financing or warrant exercises) can impact share structure and valuation.
More from Insider Trading